Document is current
Any future updates will be listed below
-
Authors
Powderly, John
Carthon, Bradley
Ernstoff, Marc
Olszanski, Anthony
Wrangle, John
Shields, Anthony
Piha-Paul, Sarina
Curtis, Kelly
Bidollari, Ilda
Du, Yangchun
Sun, Lei
Putiri, Emily
Wang, Yan
Losey, Heather
Dezube, Bruce
Dezube, Bruce
Vaishampayan, Ulka
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02799095 at ClinicalTrials.govnct03861793 at ClinicalTrials.govDocuments that mention this clinical trial
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
https://doi.org/10.1136/jitc-2020-000673
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
https://doi.org/10.1136/jitc-2024-010143
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial
https://doi.org/10.1136/jitc-2024-010777
New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings
https://doi.org/10.1136/ijgc-2023-004927
2022-RA-588-ESGO Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients with advanced solid tumours: ARTISTRY-1
https://doi.org/10.1136/ijgc-2022-esgo.518
347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial
https://doi.org/10.1136/jitc-2020-sitc2020.0347
740 Pattern of natural killer (NK) cell (CD16<sup>+</sup>CD56<sup>+</sup>) expansion correlates with response outcomes with nemvaleukin alfa treatment
https://doi.org/10.1136/jitc-2023-sitc2023.0740
373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2
https://doi.org/10.1136/jitc-2020-sitc2020.0373
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
https://doi.org/10.1136/jitc-2022-004913
nct03861793 at ClinicalTrials.govDocuments that mention this clinical trial
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
https://doi.org/10.1136/jitc-2020-000673
724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)
https://doi.org/10.1136/jitc-2023-sitc2023.0724
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2
https://doi.org/10.1136/jitc-2020-sitc2020.0373
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
https://doi.org/10.1136/jitc-2022-004913
Documents that mention this clinical trial
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
https://doi.org/10.1136/jitc-2020-000673
724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)
https://doi.org/10.1136/jitc-2023-sitc2023.0724
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2
https://doi.org/10.1136/jitc-2020-sitc2020.0373
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
https://doi.org/10.1136/jitc-2022-004913
- License Information
